Alopecia Areata: The Clinician and Patient Voice

October 2023 | Volume 22 | Issue 10 | 967 | Copyright © October 2023


Published online September 16, 2023

Antonella Tosti MD

Fredric Brandt Endowed Professor, Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL

Education: Increased patient and public awareness and education on AA is needed to mitigate bullying and social stigma associated with hair loss and baldness and to improve the acceptance and inclusion of patients with AA.

ACKNOWLEDGMENTS

The author wishes to thank Kalanethee Paul-Pletzer PhD, Kim Storck PharmD RPh, and Briana Betz PhD for their assistance in drafting the manuscript, Donna Frassetto for her assistance in editing the manuscript, and Trudy Grenon Stoddert ELS for preparing the manuscript for publication. All were compensated by Medscape, LLC.  

DISCLOSURES

Antonella Tosti MD is a consultant or advisor for Almirall, Bristol Myers Squibb, DS Laboratories, Eli Lilly and Company, MONAT GLOBAL, Myovant Sciences Ltd., Pfizer Inc., and Thirty Madison.

Commercial Supporter: 
Supported by an educational grant from Lilly.

REFERENCES

  1. Mesinkovska N, King B, Mirmirani P, et al. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20:S62-S68. 
  2. Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159:281-288.
  3. Lacarrubba F, Micali G, Tosti A. Scalp dermoscopy or trichoscopy. Curr Probl Dermatol. 2015;47:21-32.
  4. Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.
  5. Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ. 2010;341:c3671.
  6. Sy N, Mastacouris N, Strunk A, et al. Overall and racial and ethnic subgroup prevalences of alopecia areata, alopecia totalis, and alopecia universalis. JAMA Dermatol. 2023;159:419-423.
  7. Gelhorn HL, Cutts K, Edson-Heredia E, et al. The relationship between patient-reported severity of hair loss and health-related quality of life and treatment patterns among patients with alopecia areata. Dermatol Ther (Heidelb). 2022;12:989-997.
  8. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). The voice of the patient: alopecia areata. Public Meeting: September 11, 2017; Report: March 2018. https://www.fda.gov/media/112100/download. Accessed May 19, 2023. 
  9. Lintzeri DA, Constantinou A, Hillmann K, et al. Alopecia areata - current understanding and management. J Dtsch Dermatol Ges. 2022;20:59-90.
  10. Alhanshali L, Buontempo MG, Lo Sicco KI, et al. Alopecia areata: burden of disease, approach to treatment, and current unmet needs. Clin Cosmet Investig Dermatol. 2023;16:803-820.
  11. Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.
  12. Senna M, Ko J, Tosti A, et al. Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. s2021;38:4646-4658.
  13. King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86:359-364. 
  14. Olsen EA, Hordinsky MK, Price VH, et al; National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440-447. 
  15. Lyakhovitsky A, Aronovich A, Gilboa S, et al. Alopecia areata: a long-term follow-up study of 104 patients. J Eur Acad Dermatol Venereol. 2019;33:1602-1609.
  16. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long-term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55:438-441.
  17. Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78:15-24.
  18. Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians. Int J Dermatol. 2002;41:748-753.
  19. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83:123-130.
  20. Olsen EA, et al. SALT II: a new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016;75:1268-1270.
  21. Tosti A, Piraccini BM, Pazzaglia M, et al. Clobetasol propionate 0.05%under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96-98.
  22. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2%topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992;128:1467-1473.
  23. Lobato-Berezo A, March-Rodríguez A, Grimalt R, et al. Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study. Dermatol Ther. 2022;35:e15806.
  24. Dincer D, Tanacan E, Kose Ozkan C. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis. J Cosmet Dermatol. 2021;20:1807-1809. 
  25. Olumiant (baricitinib) [package insert]. Revised: 06/2022. Indianapolis, IN: Lilly USA, LLC; 2018. Revised: June 2022.
  26. Xing L, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043-1051.
  27. Yan D, Fan H, Chen M, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol. 2022;13:950450.
  28. Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33:850-856.
  29. King B, Ohyama M, Kwon O, et al; BRAVE-AA Investigators. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386:1687-1699.
  30. Reyes-Hadsall S, Drake L, Han JJ, et al. Shared decision-making, therapeutic choice, and decisional regret in patients with alopecia areata. JAMA Dermatol. 2022;158:1187-1191.
  31. Mahasaksiri T, Kositkuljorn C, Anuntrangsee T, Suchonwanit P. Application of topical immunotherapy in the treatment of alopecia areata: a review and update. Drug Des Devel Ther. 2021;15:1285-1298.

AUTHOR CORRESPONDENCE

Antonella Tosti MD antonellatosti1@gmail.com
Close Menu